SCHEMBL5135239

SCHEMBL5135239

CCCCn1c(CN(CCc2ccccc2)Cc2cccc(OC)c2)cnc1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
BCHE P06276 7/20 0.47
CALM1 P0DP23 1/20 0.44
CAMKK2 Q96RR4 1/20 0.44
F2R P25116 3/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
TLR7 Q9NYK1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5072212 0.93 BCHE (0.49) BCHEPPARGPPARA
SCHEMBL5135378 0.92 CALM1 (0.45) BCHECALM1CAMKK2F2RHSP90AA1
SCHEMBL5134787 0.91 BCHE (0.42) BCHESIGMAR1
SCHEMBL5137845 0.89 HTR2A (0.54) GAAMAPT
SCHEMBL5137926 0.89 TSHR (0.41) BCHEPPARGPPARAMAPT
SCHEMBL5075074 0.88 TSHR (0.46) BCHE
SCHEMBL5135808 0.86 L3MBTL1 (0.43) SIGMAR1
SCHEMBL5137544 0.86 HSP90AA1 (0.39) BCHEHSP90AA1HSP90AB1
SCHEMBL5135358 0.86 HSD11B1 (0.42) BCHE
SCHEMBL648541 0.85 BCHE (0.42) BCHEPPARGPPARAMAPTTLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed